Eli Lilly and Company’s projections for next year exceed Wall Street projections for the drug manufacturer, predicting 2022 revenue of $27.8 billion to $28.3 billion.
Biogen Inc. said on November 9 the company was investigating the death of a 75-year-old patient who had taken the newly approved Alzheimer’s drug Aduhelm, adding that it was not yet known whether the death was related to the treatment.
Researchers with the University of Cambridge for the first time leveraged human data to quantify the speed of various processes in the brain that lead to Alzheimer’s disease.
Eli Lilly and Co. on March 14 said the company’s experimental Alzheimer’s drug slowed the rate of decline in a measure of cognition and function by 32 percent compared with a placebo in a mid-stage trial of patients at an early stage of the mind wasting disease.
Researchers at Massachusetts General Hospital developed an artificial intelligence (AI) that quickly identifies drugs currently available that might treat Alzheimer’s disease.
RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.
A panel of outside advisers to the U.S. Food and Drug Administration voted that one of two large studies on Biogen Inc.’s experimental Alzheimer’s disease drug cannot be viewed alone without regard for the other failed trial.
A study published in the Journal of the American Medical Association shows that a new blood test may be helpful for detecting Alzheimer’s disease as early as 20 years before the onset of cognitive impairment.
Denali Therapeutics and development partner Sanofi announced data from the Phase Ib trial of DNL747 in Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). After apparent disappointing results, the companies have chosen to pause the studies with the drug and shift their resources to a similar drug, DNL788, for the same indications.
Little headway has been made in developing a treatment for Alzheimer’s disease, but that could be changing.
